NASDAQ$MODVQ

Modivcare Inc · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

Reported solid first quarter results with revenue growth and maintained 2023 outlook.

Modivcare reported a 15.3% increase in service revenue, driven by growth across all segments. The company maintained its 2023 revenue and Adjusted EBITDA guidance.

  • Service revenue increased by 15.3% to $662.3 million compared to Q1 2022.
  • Net loss was $4.0 million, or $0.28 per diluted common share.
  • Adjusted EPS was $1.42 per diluted common share.
  • The company maintained its 2023 revenue and Adjusted EBITDA guidance.

Headline financials

Total Revenue

$662M

Previous: $574M+15.3%
EPS (adj)

$1.42

Previous: $1.57-9.6%
Capital Expenditures

-$13.3M

Previous: -$8.58M-55.2%
Free Cash Flow

-$16M

Previous: $60.5M-126.4%
Net Income

-$3.96M

Previous: $318K-1345.9%
Operating Income

$8.1M

Previous: $14.9M-45.6%
Gross Profit

$112M

Previous: $115M-2.7%
Cash & Equivalents

$12.8M

Previous: $194M-93.4%
Total Assets

$1.94B

Previous: $2.11B-8.1%
Stock-Based Comp

$1.12M

Previous: $2.05M-45.1%

Revenue & EPS history

Modivcare · Revenue · Quarterly

$662M

Q1 2023+15.3%vs Q1 2022
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Forward guidance

Modivcare maintained its 2023 revenue and Adjusted EBITDA guidance. Revenue is expected to be between $2.575 billion and $2.600 billion. Adjusted EBITDA is expected to be between $225 million and $235 million.

Tailwinds

  • Recent new contract wins
  • Strong pipeline for new business
  • Continued success of Home business
  • Shift to home-based care
  • Initiatives implemented over the past few quarters will drive efficiencies and operating leverage throughout the year

Headwinds

  • Government or private insurance program funding reductions or limitations
  • Alternative payment models or the transition of Medicaid and Medicare beneficiaries to Managed Care Organizations, or MCOs
  • Inability to control reimbursement rates received for services
  • Cost containment initiatives undertaken by private third-party payors
  • Effects of a public health emergency

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 6 quarterly earnings reports

Historical avg

+0.1%

Avg return

Earnings day

-10.6%

Avg return

5 days after

+29.9%

Avg return

30 days after

53%

33 / 62 earnings

Positive

+21.0%

Q1 2024

Best reaction

-41.0%

Q4 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025
Q2 2025
Q1 2025-11.4%-26.5%+198.5%
Q4 2024-22.5%-35.9%-68.1%
Q3 2024+10.6%-0.7%+11.3%
Q2 2024+15.8%+18.8%+59.8%
Q1 2024+21.0%+18.5%+23.0%
Q4 2023-41.0%-37.7%-44.9%
Q3 2023+14.5%
Q2 2023-4.4%
Q1 2023-21.6%
Q4 2022-1.6%
Q3 2022-5.9%
Q2 2022+2.0%
Q1 2022-7.2%
Q4 2021+16.5%
Q3 2021-8.8%
Q2 2021-1.2%
Q1 2021+2.0%
Q4 2020-15.4%
Q3 2020+4.1%
Q2 2020+8.8%
Q1 2020+7.9%
Q4 2019-9.2%
Q3 2019+5.2%
Q2 2019+2.6%
Q1 2019+2.3%
Q4 2018+0.1%
Q3 2018+11.4%
Q2 2018-9.3%
Q1 2018-6.3%
Q4 2017+7.6%
Q3 2017+5.2%
Q2 2017+0.0%
Q1 2017+10.3%
Q4 2016+8.8%
Q3 2016-7.0%
Q2 2016-1.7%
Q1 2016-0.8%
Q4 2015+16.3%
Q3 2015-14.6%
Q2 2015-0.8%
Q1 2015+12.2%
Q4 2014+9.9%
Q3 2014-11.3%
Q2 2014+17.8%
Q1 2014-2.7%
Q4 2013-10.4%
Q3 2013-11.7%
Q2 2013+0.7%
Q1 2013+6.7%
Q4 2012+5.1%
Q3 2012+16.4%
Q2 2012-14.7%
Q1 2011-0.9%
Q1 2012+0.6%
Q4 2009-2.2%
Q4 2011-2.2%
Q3 2010-2.3%
Q3 2011-2.3%
Q2 2011+4.3%
Q2 2010+4.3%
Q4 2010+4.3%
Q1 2010+1.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro